Table 1.

Participant Characteristics.

Participant (SCOPE ID)	Sex	Age	Viral load (copies/mL)	CD4+ T-cell count (cells per μL)	Time of infection before initiation of therapy (months)	ART duration (years)	Therapeutic regimen	Cell Subsets Available
2302	male	27	<40	696	<6	4.6	FPV,RTV, TDF/FTC	Naïve, CM, TM, EM
2115	male	51	<40	601	<6	17.3	FTC/TDF,NVP	HLA-DR+, HLA-DR-, CM, TM, EM
2275	male	47	<40	1842	<6	15.3	FTC/TDF,NVP	HLA-DR+, HLA-DR-, CM, TM, EM
2452	male	66	<40	604	>12	3.2	MVC,RTG,ETR	Naïve, CM, TM, EM
2026	male	59	<40	476	>12	17.7	TDF,ABC/3TC,RTV,DRV	HLA-DR+, HLA-DR-, Naïve, CM, TM, EM
2046	male	50	<40	1099	>12	16.3	ECV, EFV/TDF/FTC	HLA-DR+, HLA-DR-, Naïve, CM, TM, EM

Viral Load, CD4+ T-cell count and ART duration are all as at the time of sampling. FPV, fosamprenavir; RTV, ritonavir; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; NVP, nevirapine; MVC, maraviroc; RTG, raltegravir; ETR, Etravirine; ABC, abacavir; 3TC, lamivudine; DRV, darunavir; EFV, efavirenz; ECV, entecavir; CM, Central Memory; TM; Transitional Memory; EM, Effector Memory